
  
    
      
        Introduction_NNP
        Although_IN conflicting_JJ findings_NNS about_IN bone_NN mineral_NN density_NN
        (_( BMD_NNP )_) in_IN patients_NNS with_IN type_NN 2_CD diabetes_NN have_VBP been_VBN reported_VBN ,_,
        there_EX are_VBP substantial_JJ data_NNS which_WDT support_VBP the_DT notion_NN that_DT
        type_NN 2_CD diabetes_NN is_VBZ associated_VBN with_IN increased_VBN BMD_NNP [_NN 1_CD ,_, 2_CD ,_,
        3_CD ]_NN ._. The_DT Rotterdam_NNP Study_NNP [_NN 2_CD ]_NN ,_, which_WDT involved_VBD 5_CD ,_, 931_CD
        subjects_NNS ,_, including_VBG 243_CD men_NNS and_CC 355_CD women_NNS with_IN type_NN 2_CD
        diabetes_NN ,_, provides_VBZ the_DT most_RBS convincing_JJ evidence_NN ._. They_PRP found_VBD
        that_IN diabetic_JJ men_NNS and_CC women_NNS had_VBD increased_VBN BMD_NNP independent_JJ
        of_IN age_NN ,_, obesity_NN ,_, the_DT use_NN of_IN estrogen_NN ,_, thiazide_NN ,_, or_CC loop_NN
        diuretics_NNS ,_, impairment_NN in_IN the_DT ability_NN of_IN daily_JJ living_NN ,_, and_CC
        smoking_NN [_NN 2_CD ]_NN ._. Furthermore_RB ,_, hyperinsulinemia_NN has_VBZ been_VBN
        reported_VBN to_TO be_VB associated_VBN with_IN an_DT increased_VBN BMD_NNP in_IN diabetic_JJ
        [_NN 4_CD ]_NN and_CC non-diabetic_JJ subjects_NNS [_NN 5_CD ]_NN ._. From_IN the_DT Rancho_NNP
        Bernardo_NNP Study_NNP [_NN 5_CD ]_NN ,_, the_DT level_NN of_IN fasting_VBG insulin_NN was_VBD
        significantly_RB and_CC positively_RB associated_VBN with_IN BMD_NNP in_IN
        non-diabetic_JJ female_JJ subjects_NNS ,_, where_WRB each_DT 10_CD Î¼U_NN /_NN ml_NN increase_NN
        in_IN fasting_VBG insulin_NN level_NN was_VBD associated_VBN with_IN an_DT increase_NN of_IN
        BMD_NNP by_IN 0_CD ._. 33_CD g_SYM /_NN cm_NN 2_CD in_IN the_DT radius_JJ and_CC 0_CD ._. 57_CD g_SYM /_NN cm_NN 2_CD in_IN the_DT
        spine_NN ._. However_RB ,_, no_DT independent_JJ association_NN between_IN fasting_VBG
        insulin_NN level_NN and_CC BMD_NNP was_VBD noted_VBN in_IN males_NNS [_NN 5_CD ]_NN ._. Since_IN
        fasting_VBG insulin_NN level_NN is_VBZ an_DT indicator_NN of_IN insulin_NN
        resistance_NN ,_, it_PRP is_VBZ tempting_JJ to_TO hypothesize_NN that_DT insulin_NN
        resistance_NN (_( decreased_VBD insulin_NN sensitivity_NN )_) is_VBZ associated_VBN
        with_IN increased_VBN BMD_NNP ._.
        BMD_NNP is_VBZ known_VBN to_TO have_VB strong_JJ genetic_JJ determinants_NNS ._. Our_PRP$
        understanding_NN of_IN the_DT relationship_NN between_IN BMD_NNP and_CC VDR_NNP gene_NN
        polymorphism_NN is_VBZ based_VBN on_IN a_DT twin_JJ study_NN of_IN serum_NN osteocalcin_NN
        level_NN [_NN 6_CD ]_NN ._. The_DT synthesis_NN of_IN osteocalcin_NN ,_, the_DT most_RBS abundant_JJ
        non-collageous_JJ protein_NN in_IN bone_NN ,_, is_VBZ induced_VBN by_IN calcitriol_NN
        (_( the_DT active_JJ form_NN of_IN vitamin_NN D_NNP )_) through_IN the_DT VDR_NNP ._. Since_IN a_DT
        variation_NN in_IN serum_NN osteocalcin_NN level_NN was_VBD shown_VBN to_TO have_VB a_DT
        strong_JJ genetic_JJ component_NN mediated_JJ through_IN the_DT VDR_NNP ,_, the_DT
        relationship_NN between_IN VDR_NNP polymorphisms_NNS and_CC serum_NN
        osteocalcin_NN level_NN was_VBD found_VBN ._. Furthermore_RB ,_, this_DT relationship_NN
        was_VBD shown_VBN to_TO be_VB independent_JJ of_IN age_NN or_CC menopausal_NN effect_NN [_NN
        7_CD ]_NN ._. Subsequently_RB ,_, the_DT VDR_NNP gene_NN polymorphisms_NNS were_VBD found_VBN to_TO
        account_VB for_IN 75_CD %_NN of_IN the_DT total_JJ genetic_JJ effect_NN on_IN BMD_NNP in_IN
        healthy_JJ people_NNS [_NN 8_CD ]_NN ._. However_RB ,_, to_TO date_NN there_EX are_VBP more_JJR than_IN
        50_CD studies_NNS on_IN the_DT relationship_NN between_IN VDR_NNP gene_NN
        polymorphisms_NNS and_CC BMD_NNP [_NN 9_CD ]_NN ._. About_IN half_NN of_IN the_DT studies_NNS found_VBD
        a_DT significant_JJ association_NN ,_, and_CC the_DT other_JJ half_NN found_VBD no_DT
        association_NN [_NN 9_CD ]_NN ._. The_DT most_RBS convincing_JJ evidence_NN comes_VBZ from_IN a_DT
        study_NN of_IN peak_NN BMD_NNP in_IN a_DT group_NN of_IN pre-pubertal_JJ girls_NNS [_NN 10_CD ]_NN ,_,
        which_WDT confirms_VBZ the_DT relationship_NN between_IN VDR_NNP gene_NN
        polymorphism_NN and_CC BMD_NNP ._.
        Since_IN the_DT VDR_NNP is_VBZ expressed_VBN in_IN tissues_NNS ,_, namely_RB muscle_NN and_CC
        pancreatic_JJ islets_NNS [_NN 11_CD ,_, 12_CD ,_, 13_CD ,_, 14_CD ]_NN ,_, which_WDT are_VBP involved_VBN in_IN
        the_DT regulation_NN of_IN glucose_NN metabolism_NN ,_, we_PRP hypothesized_VBN that_IN
        the_DT VDR_NNP gene_NN could_MD play_VB a_DT role_NN in_IN glucose_NN metabolism_NN ._. In_IN
        this_DT study_NN ,_, we_PRP examined_VBD the_DT role_NN of_IN the_DT 
        Fok_NNP I_PRP polymorphism_NN in_IN the_DT translation_NN
        initiation_NN codon_NN of_IN the_DT VDR_NNP gene_NN in_IN 49_CD healthy_JJ ,_, glucose_NN
        tolerant_NN Caucasians_NNP who_WP underwent_VBD a_DT standard_JJ oral_JJ glucose_NN
        tolerance_NN test_NN ._. The_DT insulin_NN sensitivity_NN and_CC beta_NN cell_NN
        function_NN were_VBD estimated_VBN using_VBG a_DT homeostasis_NNS model_NN
        assessment_NN (_( HOMA_NNP )_) [_NN 15_CD ]_NN ._. We_PRP found_VBD that_IN the_DT 
        Fok_NNP I_PRP polymorphism_NN is_VBZ associated_VBN with_IN
        insulin_NN resistance_NN in_IN a_DT Caucasian_NNP population_NN ._.
      
      
        Results_NNS
        
          Characteristics_NNP of_IN the_DT study_NN population_NN
          Since_IN hypertension_NN is_VBZ associated_VBN with_IN insulin_NN
          resistance_NN [_NN 16_CD ]_NN ,_, only_RB those_DT with_IN normal_JJ blood_NN pressure_NN
          (_( systolic_JJ blood_NN pressure_NN less_JJR than_IN 140_CD mmHg_NN and_CC diastolic_JJ
          blood_NN pressure_NN less_JJR than_IN 90_CD mmHg_NN )_) were_VBD enrolled_VBN into_IN the_DT
          study_NN ._. Because_IN we_PRP were_VBD also_RB concerned_VBN about_IN the_DT effect_NN of_IN
          glucose_NN toxicity_NN on_IN beta_NN cell_NN function_NN and_CC insulin_NN
          sensitivity_NN [_NN 17_CD ]_NN ,_, all_DT subjects_NNS underwent_VBD a_DT standard_JJ
          75_CD -_: gm_NN oral_JJ glucose_NN tolerance_NN test_NN ._. Only_RB those_DT subjects_NNS
          with_IN a_DT fasting_VBG plasma_NN glucose_NN level_NN less_JJR than_IN 6_CD ._. 1_CD mM_NN ,_,
          interval_NN plasma_NN glucose_NN levels_NNS (_( at_IN 30_CD ,_, 60_CD ,_, and_CC 90_CD
          minutes_NNS )_) less_JJR than_IN 11_CD ._. 1_LS mM_NN ,_, and_CC two-hour_JJ plasma_NN glucose_NN
          level_NN less_JJR than_IN 7_CD ._. 8_CD mM_NN were_VBD enrolled_VBN in_IN this_DT study_NN ._.
          This_DT study_NN included_VBD 49_CD healthy_JJ Caucasian_NNP subjects_NNS ,_, of_IN
          which_WDT 28_CD were_VBD female_JJ ._. Clinical_NNP features_NNS of_IN the_DT subjects_NNS
          were_VBD :_: mean_VB age_NN 28_CD years_NNS old_JJ (_( range_NN :_: 19_CD -_: 39_CD years_NNS )_) ,_, mean_VB
          body_NN mass_NN index_NN 24_CD ._. 26_CD kg_NN /_NN cm_NN 2_CD (_( 17_CD ._. 58_CD -_: 34_CD ._. 26_CD kg_NN /_NN cm_NN 2_LS )_) ,_, mean_VB
          waist-hip_JJ ratio_NN 0_CD ._. 80_CD cm_NN /_NN cm_NN (_( 0_CD ._. 65_CD -_: 1_CD ._. 03_CD cm_NN /_NN cm_NN )_) ,_, mean_VB
          systolic_JJ blood_NN pressure_NN 113_CD mmHg_NN (_( 94_CD -_: 135_CD mmHg_NN )_) ,_, mean_VB
          diastolic_JJ blood_NN pressure_NN 67_CD mmHg_NN (_( 53_CD -_: 83_CD mmHg_NN )_) ,_, mean_VB
          fasting_VBG plasma_NN glucose_NN level_NN 4_CD ._. 71_CD mM_NN (_( 3_CD ._. 88_CD -_: 5_CD ._. 54_CD mM_NN )_) ,_, mean_VB
          30_CD -_: minute_NN post_NN challenged_VBD plasma_NN glucose_NN level_NN 7_CD ._. 40_CD mM_NN
          (_( 5_CD ._. 34_CD -_: 9_CD ._. 66_CD mM_NN )_) ,_, mean_VB 60_CD -_: minute_NN post_NN challenged_VBD plasma_NN
          glucose_NN level_NN 9_CD ._. 09_CD mM_NN (_( 3_CD ._. 79_CD -_: 10_CD ._. 20_CD mM_NN )_) ,_, mean_VB 90_CD -_: minute_NN
          post_NN challenged_VBD plasma_NN glucose_NN level_NN 6_CD ._. 30_CD mM_NN (_( 3_CD ._. 12_CD -_: 9_CD ._. 02_CD
          mM_NN )_) ,_, and_CC mean_VB two-hour_JJ post_NN challenged_VBD plasma_NN glucose_NN
          level_NN 5_CD ._. 71_CD mM_NN (_( 2_CD ._. 94_CD -_: 7_CD ._. 60_CD mM_NN )_) ._.
        
        
          Genotype_NNP ,_, phenotype_NN ,_, and_CC biochemical_JJ
          association_NN
          After_IN genotyping_VBG ,_, we_PRP identified_VBD 18_CD FF_NNP ,_, 21_CD Ff_NNP ,_, and_CC 10_CD
          ff_NN subjects_NNS ._. In_IN this_DT Caucasian_NNP population_NN ,_, the_DT allele_NN
          frequency_NN was_VBD 58_CD %_NN for_IN the_DT F_NN allele_NN and_CC 42_CD %_NN for_IN the_DT f_SYM
          allele_NN ._. The_DT distribution_NN of_IN genotypes_NNS was_VBD in_IN compliance_NN
          with_IN the_DT Hardy-_NNP Weinberg_NNP equilibrium_NN (_( p_NN =_SYM 0_CD ._. 873_CD )_) ._. Since_IN only_RB
          10_CD ff_NN subjects_NNS were_VBD identified_VBN ,_, they_PRP were_VBD pooled_VBN with_IN the_DT
          Ff_NNP subjects_NNS ._. Two_CD groups_NNS (_( FF_NNP vs_NNS ._. Ff_NNP /_NN ff_NN )_) had_VBD compatible_JJ
          gender_NN distribution_NN ,_, age_NN ,_, body_NN mass_NN index_NN ,_, systolic_JJ and_CC
          diastolic_JJ blood_NN pressure_NN ,_, fasting_VBG lipid_NN profiles_NNS and_CC
          fasting_VBG plasma_NN glucose_NN level_NN (_( Table_NNP 1_LS )_) ._. However_RB ,_, the_DT
          Ff_NNP /_NN ff_NN subjects_NNS had_VBD a_DT higher_JJR mean_NN waist-hip_JJ ratio_NN and_CC a_DT
          higher_JJR mean_NN fasting_VBG plasma_NN insulin_NN level_NN ,_, compared_VBN to_TO the_DT
          FF_NNP subjects_NNS (_( p_NN =_SYM 0_CD ._. 042_CD and_CC p_NN =_SYM 0_CD ._. 006_CD ,_, respectively_RB )_) ._. These_DT
          results_NNS indicate_VBP that_IN the_DT Ff_NNP /_NN ff_NN subjects_NNS are_VBP more_JJR obese_NN
          and_CC more_JJR insulin_NN resistant_JJ than_IN the_DT FF_NNP subjects_NNS ._.
          Beta_NN cell_NN function_NN (_( %_NN B_NNP )_) and_CC insulin_NN sensitivity_NN (_( %_NN S_NNP )_)
          were_VBD estimated_VBN from_IN the_DT HOMA_NNP based_VBN on_IN the_DT average_NN of_IN
          three_CD fasting_VBG plasma_NN glucose_NN and_CC insulin_NN levels_NNS before_IN
          the_DT oral_JJ glucose_NN tolerance_NN test_NN ._. No_DT difference_NN was_VBD noted_VBN
          in_IN %_NN B_NNP between_IN the_DT two_CD groups_NNS (_( p_NN =_SYM 0_CD ._. 23_CD )_) ._. However_RB ,_, there_EX was_VBD
          a_DT drastic_JJ difference_NN in_IN %_NN S_NNP between_IN the_DT two_CD groups_NNS
          (_( p_NN =_SYM 0_CD ._. 006_CD )_) ._. After_IN an_DT oral_JJ glucose_NN load_NN (_( Figure_NN 1_LS )_) ,_, the_DT
          Ff_NNP /_NN ff_NN subjects_NNS had_VBD similar_JJ plasma_NN glucose_NN levels_NNS at_IN each_DT
          time_NN point_NN compared_VBN to_TO the_DT FF_NNP subjects_NNS ._. However_RB ,_, the_DT
          Ff_NNP /_NN ff_NN subjects_NNS had_VBD higher_JJR postchallenged_JJ insulin_NN levels_NNS
          at_IN 30_CD ,_, 60_CD ,_, and_CC 90_CD minutes_NNS than_IN the_DT FF_NNP subjects_NNS (_( p_NN =_SYM 0_CD ._. 009_CD ,_,
          p_NN =_SYM 0_CD ._. 049_CD ,_, and_CC p_NN =_SYM 0_CD ._. 041_CD ,_, respectively_RB )_) ._. Furthermore_RB ,_, the_DT
          Ff_NNP /_NN ff_NN subjects_NNS had_VBD a_DT higher_JJR insulin_NN area_NN under_IN the_DT curve_NN
          than_IN the_DT FF_NNP subjects_NNS (_( p_NN =_SYM 0_CD ._. 009_CD )_) ._. These_DT results_NNS again_RB
          indicate_VBP that_IN the_DT Ff_NNP /_NN ff_NN subjects_NNS are_VBP more_JJR insulin_NN
          resistant_JJ than_IN the_DT FF_NNP subjects_NNS ._.
        
        
          Stepwise_NNP regression_NN analysis_NN
          Various_JJ covariates_NNS have_VBP been_VBN shown_VBN to_TO affect_VB either_CC
          beta_NN cell_NN function_NN or_CC insulin_NN sensitivity_NN or_CC both_DT ._. To_TO
          examine_VB the_DT influence_NN of_IN the_DT available_JJ covariates_NNS in_IN
          addition_NN to_TO the_DT 
          Fok_NNP I_PRP polymorphism_NN on_IN beta_NN cell_NN
          function_NN and_CC insulin_NN sensitivity_NN ,_, we_PRP employed_VBN a_DT stepwise_NN
          regression_NN analytical_JJ approach_NN ._. Age_NNP ,_, gender_NN ,_, body_NN mass_NN
          index_NN ,_, waist-hip_JJ ratio_NN ,_, and_CC systolic_JJ and_CC diastolic_JJ blood_NN
          pressure_NN were_VBD entered_VBN into_IN the_DT model_NN and_CC a_DT backward_RB
          stepwise_NN regression_NN analysis_NN was_VBD performed_VBN ._. It_PRP revealed_VBD
          that_IN the_DT 
          Fok_NNP I_PRP polymorphism_NN was_VBD an_DT
          independent_JJ determinant_NN for_IN %_NN S_NNP ,_, but_CC not_RB for_IN %_NN B_NNP (_( Table_NNP 2_LS )_) ._.
          The_DT 
          Fok_NNP I_PRP polymorphism_NN ,_, combined_VBN with_IN
          waist-hip_JJ ratio_NN ,_, explained_VBD 29_CD ._. 3_LS %_NN of_IN the_DT variance_NN in_IN %_NN S_NNP ._.
          This_DT result_NN confirms_VBZ that_IN this_DT polymorphism_NN is_VBZ an_DT
          independent_JJ risk_NN factor_NN for_IN insulin_NN resistance_NN ._.
        
      
      
        Discussion_NNP
        We_PRP found_VBD that_IN in_IN healthy_JJ ,_, normotensive_JJ Caucasian_NNP
        subjects_NNS with_IN normal_JJ glucose_NN tolerance_NN ,_, the_DT 
        Fok_NNP I_PRP polymorphism_NN in_IN the_DT vitamin_NN D_NNP
        receptor_NN gene_NN accounted_VBD for_IN 15_CD ._. 2_LS %_NN of_IN the_DT variance_NN in_IN %_NN S_NNP ,_,
        but_CC had_VBD no_DT impact_NN on_IN %_NN B_NNP ._. Although_IN the_DT Ff_NNP /_NN ff_NN subjects_NNS were_VBD
        more_JJR obese_NN than_IN the_DT FF_NNP subjects_NNS (_( p_NN =_SYM 0_CD ._. 042_CD for_IN waist-hip_JJ
        ratio_NN )_) ,_, the_DT difference_NN in_IN %_NN S_NNP between_IN the_DT two_CD groups_NNS
        decreased_VBD after_IN adjusting_VBG for_IN waist-hip_JJ ratio_NN (_( 0_CD ._. 50_CD vs_NNS ._.
        0_CD ._. 69_CD before_IN and_CC 0_CD ._. 52_CD vs_NNS ._. 0_CD ._. 65_CD after_IN adjusting_VBG for_IN waist-hip_JJ
        ratio_NN )_) ._. However_RB ,_, this_DT polymorphism_NN remained_VBD an_DT independent_JJ
        determinant_NN for_IN %_NN S_NNP after_IN adjusting_VBG for_IN waist-hip_JJ ratio_NN
        (_( p_NN =_SYM 0_CD ._. 039_CD Figure_NN 2_LS )_) ._. Therefore_RB ,_, we_PRP concluded_VBD that_IN the_DT 
        Fok_NNP I_PRP polymorphism_NN was_VBD a_DT risk_NN factor_NN
        for_IN insulin_NN resistance_NN ,_, independent_JJ of_IN obesity_NN ._.
        The_DT allelic_JJ frequencies_NNS of_IN the_DT present_JJ study_NN (_( 58_CD %_NN for_IN
        the_DT F_NN allele_NN and_CC 42_CD %_NN for_IN the_DT f_SYM allele_NN )_) are_VBP very_RB similar_JJ to_TO
        the_DT reported_VBD frequencies_NNS in_IN a_DT Japanese_JJ (_( 56_CD %_NN for_IN the_DT F_NN
        allele_NN and_CC 44_CD %_NN for_IN the_DT f_SYM allele_NN )_) and_CC a_DT Caucasian_NNP (_( 59_CD %_NN for_IN
        the_DT F_NN allele_NN and_CC 41_CD %_NN for_IN the_DT f_SYM allele_NN )_) population_NN [_NN 18_CD ,_,
        19_CD ]_NN ._. In_IN the_DT present_JJ study_NN ,_, we_PRP pooled_VBN the_DT ff_NN subjects_NNS with_IN
        Ff_NNP subjects_NNS for_IN its_PRP$ small_JJ sample_NN size_NN (_( 10_CD ff_NN vs_NNS ._. 18_CD Ff_NNP and_CC
        21_CD FF_NNP )_) ._. To_TO examine_VB whether_IN there_EX is_VBZ a_DT difference_NN among_IN the_DT
        three_CD genotypic_JJ groups_NNS ,_, we_PRP examined_VBD the_DT influence_NN of_IN
        genotypes_NNS on_IN %_NN S_NNP and_CC %_NN B_NNP by_IN ANOVA_NNP ._. We_PRP found_VBD a_DT significant_JJ
        difference_NN in_IN %_NN S_NNP (_( p_NN =_SYM 0_CD ._. 016_CD )_) and_CC again_RB no_DT difference_NN in_IN %_NN B_NNP
        (_( p_NN =_SYM 0_CD ._. 408_CD )_) ._. However_RB ,_, no_DT difference_NN in_IN %_NN S_NNP was_VBD noted_VBN between_IN
        the_DT Ff_NNP and_CC ff_NN groups_NNS (_( p_NN =_SYM 0_CD ._. 159_CD )_) ._. The_DT main_JJ difference_NN in_IN %_NN S_NNP
        is_VBZ between_IN the_DT FF_NNP and_CC Ff_NNP groups_NNS (_( p_NN =_SYM 0_CD ._. 007_CD )_) ._. Although_IN we_PRP
        cannot_NN exclude_VBP the_DT possibility_NN of_IN inadequate_JJ power_NN to_TO
        detect_VB the_DT difference_NN from_IN the_DT present_JJ sample_NN size_NN ,_, this_DT
        observation_NN is_VBZ consistent_JJ with_IN the_DT functional_JJ study_NN of_IN the_DT 
        Fok_NNP I_PRP polymorphism_NN in_IN cultured_JJ human_JJ
        peripheral_JJ blood_NN mononuclear_NN cells_NNS [_NN 20_CD ]_NN ._. In_IN this_DT
        functional_JJ study_NN ,_, they_PRP compared_VBD the_DT inhibitory_NN effect_NN of_IN
        1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP 
        3_CD on_IN the_DT growth_NN of_IN cultured_JJ human_JJ
        peripheral_JJ mononuclear_NN cells_NNS isolated_VBN from_IN subjects_NNS with_IN
        different_JJ 
        Fok_NNP I_PRP genotypes_NNS and_CC found_VBD significant_JJ
        differences_NNS among_IN the_DT three_CD genotypes_NNS ,_, but_CC found_VBD no_DT
        difference_NN between_IN the_DT Ff_NNP and_CC ff_NN groups_NNS [_NN 20_CD ]_NN ._.
        Obesity_NNP is_VBZ well_RB known_VBN to_TO be_VB associated_VBN with_IN insulin_NN
        resistance_NN [_NN 21_CD ]_NN ._. In_IN the_DT present_JJ study_NN ,_, we_PRP also_RB found_VBD that_IN
        the_DT 
        Fok_NNP I_PRP polymorphism_NN was_VBD associated_VBN
        with_IN obesity_NN assessed_VBN by_IN waist-hip_JJ ratio_NN but_CC not_RB by_IN body_NN
        mass_NN index_NN (_( Table_NNP 1_LS )_) ._. However_RB ,_, the_DT association_NN between_IN the_DT
        Ff_NNP /_NN ff_NN genotypes_NNS with_IN both_DT insulin_NN resistance_NN and_CC obesity_NN
        prompted_VBD us_PRP to_TO further_VB examine_VB the_DT interaction_NN among_IN this_DT
        polymorphism_NN ,_, obesity_NN ,_, and_CC insulin_NN resistance_NN ._. Multivariate_NNP
        analysis_NN revealed_VBD that_IN this_DT polymorphism_NN had_VBD no_DT independent_JJ
        impact_NN on_IN waist-hip_JJ ratio_NN (_( p_NN =_SYM 0_CD ._. 1468_CD )_) after_IN adjustment_NN for_IN
        age_NN (_( p_NN =_SYM 0_CD ._. 0203_CD )_) ,_, gender_NN (_( p_NN =_SYM 0_CD ._. 0007_CD )_) and_CC body_NN mass_NN index_NN (_( p_NN
        <_NN 0_CD ._. 0001_CD )_) ,_, while_IN systolic_JJ and_CC diastolic_JJ blood_NN pressure_NN
        had_VBD also_RB no_DT impact_NN on_IN waist-hip_JJ ratio_NN (_( p_NN =_SYM 0_CD ._. 5549_CD and_CC
        p_NN =_SYM 0_CD ._. 3806_CD ,_, respectively_RB )_) ._. However_RB ,_, from_IN the_DT multivariate_NN
        analysis_NN result_NN of_IN %_NN S_NNP (_( Table_NNP 2_LS )_) ,_, we_PRP concluded_VBD that_IN this_DT
        polymorphism_NN had_VBD an_DT important_JJ impact_NN on_IN insulin_NN
        sensitivity_NN ,_, which_WDT was_VBD independent_JJ of_IN the_DT influence_NN of_IN
        waist-hip_JJ ratio_NN ._. Although_IN gender_NN was_VBD excluded_VBN as_IN an_DT
        independent_JJ covariate_NN for_IN %_NN S_NNP in_IN the_DT present_JJ study_NN after_IN
        adjustment_NN for_IN waist-hip_JJ ratio_NN ,_, which_WDT was_VBD affected_VBN by_IN
        gender_NN ,_, the_DT interaction_NN between_IN gender_NN and_CC this_DT
        polymorphism_NN ,_, if_IN any_DT ,_, needs_VBZ to_TO be_VB addressed_VBN in_IN a_DT study_NN with_IN
        a_DT much_RB larger_JJR sample_NN size_NN ._.
        The_DT role_NN of_IN VDR_NNP gene_NN polymorphisms_NNS has_VBZ been_VBN examined_VBN in_IN
        four_CD groups_NNS of_IN diabetic_JJ patients_NNS ,_, however_RB their_PRP$ roles_NNS in_IN
        insulin_NN sensitivity_NN have_VBP not_RB been_VBN examined_VBN ._. In_IN 93_CD Southern_NNP
        Indian_JJ families_NNS with_IN type_NN 1_CD diabetes_NN ,_, transmission_NN
        disequilibrium_NN testing_NN analysis_NN demonstrated_VBD the_DT
        preferential_JJ transmission_NN of_IN the_DT "_'' b_SYM "_'' allele_NN of_IN the_DT 
        Bsm_NNP I_PRP polymorphism_NN to_TO affected_VBN
        subjects_NNS [_NN 22_CD ]_NN ._. However_RB ,_, it_PRP was_VBD less_RBR certain_JJ for_IN the_DT 
        Taq_NNP I_PRP and_CC 
        Apa_NNP I_PRP polymorphisms_NNS in_IN this_DT sample_NN
        set_VBN ._. Nonetheless_RB ,_, this_DT study_NN indicates_VBZ that_IN the_DT 
        Bsm_NNP I_PRP polymorphism_NN at_IN the_DT VDR_NNP gene_NN
        locus_JJ is_VBZ a_DT risk_NN factor_NN of_IN type_NN 1_CD diabetes_NN ._. In_IN a_DT study_NN of_IN
        152_CD Caucasian_NNP families_NNS with_IN type_NN 1_CD diabetes_NN ,_, there_EX was_VBD an_DT
        excessive_JJ transmission_NN of_IN bT_NN and_CC bAT_NN extended_VBD haplotypes_NNS to_TO
        affected_VBN individuals_NNS but_CC no_DT evidence_NN of_IN excessive_JJ
        transmission_NN of_IN 
        Taq_NNP I_PRP and_CC 
        Apa_NNP I_PRP alleles_NNS alone_RB [_NN 23_CD ]_NN ._. Recently_RB ,_,
        we_PRP confirmed_VBD the_DT association_NN of_IN this_DT marker_NN with_IN type_NN 1_CD
        diabetes_NN in_IN a_DT Taiwanese_JJ population_NN [_NN 24_CD ]_NN ._. These_DT studies_NNS in_IN
        two_CD different_JJ populations_NNS indicate_VBP that_IN the_DT 
        Bsm_NNP I_PRP polymorphism_NN at_IN the_DT VDR_NNP gene_NN
        locus_JJ confers_VBZ susceptibility_NN to_TO type_NN 1_CD diabetes_NN ._. The_DT study_NN
        of_IN type_NN 2_CD diabetes_NN with_IN the_DT VDR_NNP gene_NN included_VBD 164_CD
        Bangladesh_NNP Asians_NNPS who_WP were_VBD at_IN risk_NN for_IN type_NN 2_CD diabetes_NN and_CC
        25_CD %_NN of_IN them_PRP were_VBD either_CC diabetic_JJ or_CC impaired_VBN glucose_NN
        tolerant_NN ._. An_DT association_NN between_IN the_DT 
        Apa_NNP I_PRP polymorphism_NN and_CC insulin_NN
        secretion_NN index_NN was_VBD noted_VBN [_NN 25_CD ]_NN ._. These_DT studies_NNS suggest_VBP that_IN
        the_DT VDR_NNP gene_NN locus_JJ is_VBZ a_DT genetic_JJ marker_NN for_IN both_DT type_NN 1_CD and_CC
        type_NN 2_CD diabetes_NN ._.
        Since_IN the_DT 
        Bsm_NNP I_PRP polymorphism_NN is_VBZ located_VBN in_IN
        intron_NN 7_CD ,_, the_DT 
        Apa_NNP I_PRP polymorphism_NN in_IN intron_NN 8_CD ,_, and_CC
        the_DT 
        Taq_NNP I_PRP polymorphism_NN in_IN exon_NN 9_CD within_IN
        the_DT 3_CD '_POS -_: untranslated_JJ region_NN of_IN the_DT VDR_NNP gene_NN ,_, they_PRP are_VBP less_RBR
        likely_JJ to_TO have_VB any_DT biological_JJ consequences_NNS in_IN causing_VBG the_DT
        disease_NN and_CC affecting_VBG glucose_NN metabolism_NN ._. Furthermore_RB ,_,
        functional_JJ studies_NNS of_IN these_DT polymorphisms_NNS show_VBP no_DT clearly_RB
        demonstrable_JJ difference_NN among_IN them_PRP [_NN 26_CD ,_, 27_CD ,_, 28_CD ,_, 29_CD ]_NN ._. The_DT
        T-_NNP to-_NN C_NNP transition_NN polymorphism_NN at_IN the_DT translation_NN
        initiation_NN codon_NN of_IN the_DT human_JJ VDR_NNP gene_NN not_RB only_RB destroys_VBZ a_DT 
        Fok_NNP I_PRP site_NN but_CC also_RB abolishes_NNS the_DT
        first_JJ translation_NN initiation_NN codon_NN of_IN this_DT gene_NN ._. The_DT
        alternative_JJ translation_NN initiation_NN codon_NN ,_, which_WDT also_RB
        adheres_NNS the_DT first-_NN AUG_NNP rule_NN by_IN Kozak_NNP [_NN 30_CD ]_NN ,_, is_VBZ located_VBN
        downstream_JJ by_IN three_CD amino_JJ acids_NNS ._. In_IN the_DT present_JJ study_NN ,_, we_PRP
        examined_VBD the_DT 
        Fok_NNP I_PRP polymorphism_NN ,_, which_WDT not_RB only_RB
        affects_VBZ the_DT translation_NN of_IN the_DT peptide_NN ,_, but_CC also_RB affects_VBZ
        the_DT biological_JJ activity_NN tested_VBN in_IN Hela_NNP Cells_NNP [_NN 31_CD ]_NN ._. This_DT
        T-_NNP to-_NN C_NNP transition_NN resulted_VBD in_IN the_DT synthesis_NN of_IN a_DT smaller_JJR (_( F_NN
        allele_NN ,_, three_CD amino_JJ acids_NNS less_JJR than_IN the_DT f_SYM allele_NN )_) protein_NN
        with_IN increased_VBN vitamin_NN D-_NNP dependent_JJ transcriptional_NN
        activation_NN [_NN 31_CD ]_NN ._. In_IN addition_NN ,_, the_DT different_JJ response_NN to_TO
        1_CD ,_, 25_CD -_: dihydroxyvitamin_NN D_NNP is_VBZ also_RB demonstrated_VBN in_IN cultured_JJ
        human_JJ peripheral_JJ blood_NN mononuclear_NN cells_NNS from_IN subjects_NNS with_IN
        different_JJ 
        Fok_NNP I_PRP genotypes_NNS [_NN 20_CD ]_NN ._. We_PRP found_VBD that_IN
        the_DT subjects_NNS with_IN homozygous_JJ F_NN allele_NN had_VBD increased_VBN insulin_NN
        sensitivity_NN compared_VBN to_TO those_DT with_IN the_DT f_SYM allele_NN ._.
        Although_IN the_DT molecular_JJ basis_NN of_IN this_DT association_NN is_VBZ
        unclear_JJ ,_, the_DT study_NN of_IN the_DT relationship_NN between_IN the_DT level_NN of_IN
        vitamin_NN D_NNP and_CC glucose_NN tolerance_NN [_NN 32_CD ]_NN provides_VBZ some_DT insight_NN
        to_TO the_DT underlying_VBG mechanism_NN ._. Glucose_NNP tolerance_NN and_CC vitamin_NN
        D_NNP level_NN were_VBD assessed_VBN in_IN 142_CD elderly_JJ Dutchmen_NNP ._. Fasting_NNP
        insulin_NN and_CC postchallenged_JJ insulin_NN levels_NNS decreased_VBD with_IN
        increased_VBN vitamin_NN D_NNP levels_NNS [_NN 32_CD ]_NN ._. As_IN a_DT higher_JJR insulin_NN level_NN
        is_VBZ a_DT surrogate_NN for_IN decreased_VBD insulin_NN sensitivity_NN ,_, their_PRP$
        observation_NN suggests_VBZ that_IN a_DT higher_JJR vitamin_NN D_NNP level_NN is_VBZ
        associated_VBN with_IN increased_VBN insulin_NN sensitivity_NN ._. Since_IN
        vitamin_NN D_NNP binds_NNS to_TO the_DT vitamin_NN D_NNP receptor_NN to_TO initiate_VB the_DT
        downstream_JJ action_NN ,_, a_DT higher_JJR vitamin_NN D_NNP level_NN would_MD lead_VB to_TO
        an_DT increase_NN in_IN vitamin_NN D-_NNP dependent_JJ transcription_NN
        activation_NN ._. Our_PRP$ observation_NN that_IN the_DT subjects_NNS with_IN
        homozygous_JJ F_NN alleles_NNS (_( associated_VBN with_IN an_DT increased_VBN
        activity_NN )_) are_VBP more_JJR insulin_NN sensitive_JJ than_IN those_DT with_IN the_DT f_SYM
        allele_NN is_VBZ consistent_JJ with_IN the_DT notion_NN above_IN ._.
        Our_PRP$ original_JJ hypothesis_NNS was_VBD that_IN the_DT allele_NN ,_, which_WDT is_VBZ
        associated_VBN with_IN increased_VBN BMD_NNP ,_, was_VBD also_RB associated_VBN with_IN
        higher_JJR insulin_NN levels_NNS and_CC insulin_NN resistance_NN ._. However_RB ,_,
        since_IN the_DT F_NN allele_NN is_VBZ associated_VBN with_IN increased_VBN BMD_NNP [_NN 31_CD ,_,
        33_CD ]_NN ,_, our_PRP$ observation_NN of_IN the_DT association_NN between_IN the_DT F_NN
        allele_NN and_CC increased_VBN insulin_NN sensitivity_NN is_VBZ not_RB consistent_JJ
        with_IN our_PRP$ original_JJ hypothesis_NNS ._. On_IN the_DT other_JJ hand_NN ,_, not_RB all_DT
        reports_NNS support_VBP the_DT association_NN between_IN the_DT F_NN allele_NN and_CC
        increased_VBN BMD_NNP [_NN 34_CD ,_, 35_CD ]_NN ._. Nonetheless_RB ,_, our_PRP$ observation_NN shows_VBZ
        that_IN this_DT polymorphism_NN is_VBZ an_DT independent_JJ determinant_NN for_IN
        insulin_NN sensitivity_NN and_CC is_VBZ in_IN agreement_NN with_IN the_DT notion_NN
        that_IN a_DT higher_JJR level_NN of_IN vitamin_NN D_NNP is_VBZ associated_VBN with_IN
        increased_VBN insulin_NN sensitivity_NN [_NN 32_CD ]_NN ._. Furthermore_RB additional_JJ
        studies_NNS in_IN the_DT Caucasian_NNP and_CC other_JJ ethnic_JJ populations_NNS are_VBP
        required_VBN ._.
        In_IN the_DT present_JJ study_NN ,_, we_PRP report_VBP an_DT association_NN between_IN a_DT
        polymorphism_NN at_IN the_DT translation_NN initiation_NN codon_NN of_IN the_DT
        human_JJ VDR_NNP gene_NN and_CC insulin_NN sensitivity_NN in_IN glucose_NN tolerant_NN
        and_CC normotensive_JJ Caucasians_NNP ._. This_DT polymorphism_NN is_VBZ an_DT
        independent_JJ determinant_NN of_IN insulin_NN sensitivity_NN ,_, explaining_VBG
        15_CD ._. 2_LS %_NN of_IN the_DT variance_NN in_IN %_NN S_NNP and_CC with_IN waist-hip_JJ ratio_NN ,_,
        explaining_VBG 29_CD ._. 3_LS %_NN of_IN the_DT variance_NN in_IN %_NN S_NNP ._. Although_IN the_DT
        speculated_VBN mechanism_NN of_IN our_PRP$ observation_NN is_VBZ in_IN agreement_NN
        with_IN the_DT published_VBN association_NN between_IN vitamin_NN D_NNP levels_NNS and_CC
        insulin_NN sensitivity_NN ,_, further_JJ studies_NNS are_VBP required_VBN to_TO
        confirm_VB our_PRP$ observation_NN in_IN other_JJ ethnic_JJ groups_NNS as_RB well_RB as_IN
        in_IN another_DT Caucasian_NNP population_NN ._. To_TO explore_VB the_DT underlying_VBG
        molecular_JJ basis_NN of_IN the_DT 
        Fok_NNP I_PRP polymorphism_NN at_IN the_DT VDR_NNP gene_NN
        locus_JJ ,_, as_RB well_RB as_IN the_DT association_NN between_IN vitamin_NN D_NNP level_NN
        and_CC insulin_NN sensitivity_NN ,_, also_RB warrants_VBZ further_JJ study_NN ._.
      
      
        Subjects_NNP ,_, materials_NNS and_CC methods_NNS
        
          Study_NN subjects_NNS
          We_PRP confirm_VBP that_IN the_DT study_NN has_VBZ complied_VBN with_IN the_DT
          recommendations_NNS of_IN the_DT Declaration_NNP of_IN Helsinki_NNP ._. The_DT study_NN
          was_VBD approved_VBN by_IN the_DT institutional_JJ review_NN board_NN and_CC a_DT
          written_VBN informed_VBN consent_NN was_VBD obtained_VBN from_IN each_DT
          participant_NN at_IN the_DT beginning_NN of_IN the_DT study_NN ._. Subjects_NNP were_VBD
          recruited_VBN through_IN an_DT advertisement_NN on_IN a_DT campus_NN media_NNS of_IN
          this_DT institution_NN ._. Only_RB healthy_JJ subjects_NNS were_VBD invited_VBN to_TO
          participate_VB in_IN this_DT study_NN ._. They_PRP were_VBD prescreened_JJ via_IN
          telephone_NN and_CC confirmed_VBD again_RB on_IN the_DT day_NN of_IN the_DT visit_NN ._.
          They_PRP were_VBD biologically_RB unrelated_JJ ._.
        
        
          Oral_NNP glucose_NN tolerance_NN test_NN and_CC physical_JJ
          examination_NN
          Subjects_NNP were_VBD instructed_VBN to_TO fast_RB for_IN at_IN least_JJS 14_CD hours_NNS
          before_IN the_DT study_NN visit_NN ._. On_IN the_DT morning_NN of_IN the_DT visit_NN ,_, an_DT
          indwelling_VBG angiocatheter_NN was_VBD inserted_VBN into_IN an_DT antecubital_NN
          vein_NN ._. All_DT subjects_NNS had_VBD fasting_VBG blood_NN samples_NNS drawn_VBN at_IN
          -_: 15_CD ,_, -_: 10_CD ,_, and_CC -_: 5_CD minutes_NNS ._. These_DT samples_NNS were_VBD used_VBN for_IN
          glucose_NN ,_, insulin_NN ,_, lipid_NN measurement_NN and_CC genomic_JJ DNA_NNP
          isolation_NN ._. Fasting_NNP plasma_NN glucose_NN and_CC insulin_NN levels_NNS were_VBD
          calculated_VBN as_IN the_DT average_NN of_IN three_CD fasting_VBG samples_NNS ._. After_IN
          the_DT oral_JJ administration_NN of_IN 75_CD -_: gm_NN glucose_NN ,_, postchallenged_JJ
          blood_NN samples_NNS were_VBD drawn_VBN at_IN 30_CD ,_, 60_CD ,_, 90_CD ,_, and_CC 120_CD minutes_NNS
          for_IN glucose_NN and_CC insulin_NN measurements_NNS ._. A_DT limited_JJ physical_JJ
          examination_NN was_VBD performed_VBN on_IN all_DT study_NN participants_NNS ,_,
          including_VBG measurements_NNS of_IN weight_NN ,_, height_NN ,_, waist_NN ,_, hip_NN ,_, and_CC
          blood_NN pressure_NN ._. After_IN resting_VBG quietly_RB for_IN 30_CD minutes_NNS ,_,
          three_CD consecutive_JJ measurements_NNS of_IN systolic_JJ and_CC diastolic_JJ
          blood_NN pressures_NNS were_VBD taken_VBN one_CD minute_NN apart_RB ,_, and_CC the_DT
          average_NN of_IN the_DT three_CD measurements_NNS was_VBD reported_VBN ._.
        
        
          DNA_NN extraction_NN and_CC genotyping_VBG of_IN the_DT Fok_NNP I_PRP
          polymorphism_NN
          Genomic_NNP DNA_NNP was_VBD extracted_VBN from_IN peripheral_JJ lymphocytes_NNS
          as_RB previously_RB described_VBD [_NN 36_CD ]_NN ._. The_DT genomic_JJ DNA_NNP fragment_NN
          flanking_VBG the_DT 
          Fok_NNP I_PRP polymorphism_NN was_VBD amplified_VBN
          using_VBG two_CD primers_NNS flanking_VBG exon_NN 2_CD of_IN the_DT VDR_NNP gene_NN :_:
          AGCTGGCCCTGGCACTGCTCTGCTCT_NNP and_CC
          ATGGAAACACCTTGCTTCTTCTCCCTC_NNP ._. Polymerase_NNP chain_NN reaction_NN
          (_( PCR_NNP )_) was_VBD carried_VBN out_IN in_IN a_DT total_JJ volume_NN of_IN 11_CD Î¼l_NN
          containing_VBG 0_CD ._. 5_CD pM_NN of_IN each_DT primer_NN ,_, 0_CD ._. 2_CD mM_NN dNTP_NN ,_, 2_CD mM_NN MgCl_NNP 
          2_CD ,_, 5_CD %_NN dimethysulphoxide_NN (_( DMSO_NNP )_) ,_, 0_CD ._. 275_CD
          U_NNP Taq_NNP polymerase_NN ,_, 50_CD mM_NN KCl_NNP ,_, 10_CD mM_NN Tris-_NNP HCl_NNP pH_NN 8_CD ._. 3_CD ,_, and_CC
          0_CD ._. 001_CD %_NN gelatin_NN ._. The_DT region_NN of_IN interest_NN was_VBD amplified_VBN by_IN
          an_DT initial_JJ denaturation_NN at_IN 94_CD Â°_NN C_NNP for_IN 5_CD minutes_NNS ,_, 35_CD cycles_NNS
          of_IN denaturation_NN at_IN 94_CD Â°_NN C_NNP for_IN 30_CD seconds_NNS ,_, annealing_VBG at_IN 60_CD Â°_NN C_NNP
          for_IN 30_CD seconds_NNS ,_, and_CC extension_NN at_IN 72_CD Â°_NN C_NNP for_IN 30_CD seconds_NNS ,_, and_CC
          concluded_VBD with_IN a_DT final_JJ extension_NN at_IN 72_CD Â°_NN C_NNP for_IN 10_CD minutes_NNS ._.
          Then_RB ,_, 5_CD Î¼l_NN of_IN the_DT PCR_NNP product_NN (_( 265_CD base_NN pairs_NNS )_) was_VBD
          digested_VBN in_IN 15_CD -_: Î¼l_NN of_IN reaction_NN volume_NN containing_VBG 1_CD U_NNP of_IN 
          Fok_NNP I_PRP (_( New_NNP England_NNP Biolabs_NNP Inc_NNP ._. ,_,
          Beverly_NNP ,_, Massachusetts_NNP ,_, USA_NNP )_) with_IN the_DT buffer_NN supplied_VBN by_IN
          the_DT vender_NN ._. The_DT digested_VBN PCR_NNP products_NNS were_VBD resolved_VBN on_IN
          2_CD ._. 0_CD %_NN agarose_NN gels_NNS ._. 
          Fok_NNP I_PRP digested_VBN the_DT first_JJ ATG_NNP and_CC
          yielded_VBD two_CD products_NNS ,_, 69_CD and_CC 196_CD base_NN pairs_NNS (_( f_SYM allele_NN )_) ,_,
          while_IN the_DT T_NN to_TO C_NNP transition_NN destroyed_VBD the_DT 
          Fok_NNP I_PRP site_NN (_( F_NN allele_NN )_) ._.
        
        
          Statistical_NNP analysis_NN
          SYSTAT_NNP version_NN 8_CD ._. 0_CD for_IN Windows_NNP of_IN the_DT SPSS_NNP Inc_NNP ._.
          (_( Chicago_NNP ,_, Illinois_NNP ,_, USA_NNP )_) was_VBD used_VBN for_IN statistical_JJ
          analysis_NN ._. Variables_NNP with_IN skewed_VBN distributions_NNS were_VBD
          logarithmically_RB transformed_VBN before_IN analysis_NN ._. The_DT
          variables_NNS transformed_VBN were_VBD body_NN mass_NN index_NN ,_, waist-hip_JJ
          ratio_NN ,_, plasma_NN insulin_NN levels_NNS ,_, insulin_NN area_NN under_IN the_DT
          curve_NN ,_, %_NN B_NNP ,_, and_CC %_NN S_NNP ._. Data_NNP were_VBD presented_VBN as_IN mean_NN (_( or_CC
          geometric_JJ means_VBZ when_WRB appropriate_JJ )_) with_IN 95_CD %_NN confidence_NN
          intervals_NNS ,_, unless_IN otherwise_RB specified_VBN ._. Two-sided_NNP t-tests_JJ
          or_CC chi-square_JJ tests_NNS were_VBD used_VBN to_TO evaluate_VB the_DT differences_NNS
          between_IN the_DT two_CD groups_NNS ._. To_TO determine_VB the_DT interaction_NN of_IN
          the_DT genotype_NN of_IN interest_NN with_IN the_DT other_JJ covariates_NNS ,_, a_DT
          stepwise_NN regression_NN analysis_NN was_VBD performed_VBN with_IN a_DT
          backward_RB option_NN and_CC an_DT alpha-to-remove_JJ or_CC alpha-to-enter_JJ
          setting_NN at_IN 0_CD ._. 10_CD ._. The_DT covariates_NNS with_IN the_DT highest_JJS p_NN value_NN
          were_VBD removed_VBN one_CD at_IN a_DT time_NN ,_, until_IN all_PDT the_DT remaining_VBG
          covariates_NNS had_VBD a_DT p_NN value_NN less_JJR than_IN 0_CD ._. 10_CD ._.
        
      
      
        Abbreviations_NNP
        HOMA_NNP ,_, Homeostasis_NNP Model_NNP Assessment_NNP ;_: VDR_NNP ,_, vitamin_NN D_NNP
        receptor_NN ;_: BMD_NNP ,_, bone_NN mineral_NN density_NN ;_: PCR_NNP ,_, polymerase_NN chain_NN
        reaction_NN ._.
      
    
  
